See All Slides - tctmd.com

Slides

Presentation TCT 2013

Establishing a Nationwide STEMI Network (Including Primary PCI Without On-site Surgery)

Presenter: Christopher Granger

October 27, 2013

Presentation TCT 2013

Is Normalized Vasoreactivity at and Distal to the Stent Site Likely to Translate into Improved Clinical
Outcomes?

Presenter: Raimund Erbel

October 27, 2013

Presentation TCT 2013

The Case for a Bioresorbable Metallic Platform!

Presenter: Ron Waksman

October 27, 2013

Presentation TCT 2013

MiStent: 2-year Randomized Trial Results from a Sirolimus-eluting Stent with a Bioabsorbable Coating

Presenter: John Ormiston

October 27, 2013

Presentation TCT 2013

A “LIVE” Multi-Disciplinary Heart Team Case Presentation – Inoperable TAVR or Futile

Presenter: Tamim Nazif

October 27, 2013

Presentation TCT 2013

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Presenter: Andrew Farb

October 27, 2013

Presentation TCT 2013

How to be a Key Enroller in Clinical Trials: Bringing Your Colleagues Together

Presenter: Nicholas Lembo

October 27, 2013

Presentation TCT 2013

Direct Aortic Access is the Preferred (Non-transfemoral) Alternative

Presenter: Michael Reardon

October 27, 2013

Presentation TCT 2013

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Presenter: Thomas Zeller

October 27, 2013

Presentation TCT 2013

Which Aortic Stenosis Patients Are Too High-Risk for TAVR?

Presenter: Howard Herrmann

October 27, 2013

Advertisement

Slides

Establishing a Nationwide STEMI Network (Including Primary PCI Without On-site Surgery)

Is Normalized Vasoreactivity at and Distal to the Stent Site Likely to Translate into Improved Clinical
Outcomes?

The Case for a Bioresorbable Metallic Platform!

MiStent: 2-year Randomized Trial Results from a Sirolimus-eluting Stent with a Bioabsorbable Coating

A “LIVE” Multi-Disciplinary Heart Team Case Presentation – Inoperable TAVR or Futile

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

How to be a Key Enroller in Clinical Trials: Bringing Your Colleagues Together

Direct Aortic Access is the Preferred (Non-transfemoral) Alternative

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Which Aortic Stenosis Patients Are Too High-Risk for TAVR?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content